JNJ

187.25

-0.16%↓

ABT

125.61

+2.29%↑

TMO

568.13

+1.65%↑

ISRG

536.58

+0.14%↑

DHR

214.86

+0.66%↑

JNJ

187.25

-0.16%↓

ABT

125.61

+2.29%↑

TMO

568.13

+1.65%↑

ISRG

536.58

+0.14%↑

DHR

214.86

+0.66%↑

JNJ

187.25

-0.16%↓

ABT

125.61

+2.29%↑

TMO

568.13

+1.65%↑

ISRG

536.58

+0.14%↑

DHR

214.86

+0.66%↑

JNJ

187.25

-0.16%↓

ABT

125.61

+2.29%↑

TMO

568.13

+1.65%↑

ISRG

536.58

+0.14%↑

DHR

214.86

+0.66%↑

JNJ

187.25

-0.16%↓

ABT

125.61

+2.29%↑

TMO

568.13

+1.65%↑

ISRG

536.58

+0.14%↑

DHR

214.86

+0.66%↑

Home・Akcijų sąrašas・Perspective Therapeutics Inc

Perspective Therapeutics Inc

Atidarymo kaina

2.47 -5.73

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

2.46

Max

2.66

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+379.85% upside

Dividendai
By Dow Jones
Kitas uždarbis	2025-11-12

Perspective Therapeutics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-11-03 21:44; UTC

Uždarbis

Vertex Pharmaceuticals Revenue Climbs on Demand for Cystic Fibrosis Drugs

2025-11-03 23:44; UTC

Rinkos pokalbiai

Nikkei May Rise on Weaker Yen, Hopes for Govt Econ Steps -- Market Talk

2025-11-03 23:34; UTC

Rinkos pokalbiai

Gold Edges Lower Amid Lingering Worry Over China's Ending of Tax Incentive -- Market Talk

2025-11-03 23:28; UTC

Uždarbis

Palantir Revenue Hits Another Record as Defense Work Booms -- 2nd Update

2025-11-03 23:24; UTC

Uždarbis

Correct: Grab Holdings Sees FY2025 Adj Ebitda $490M-$500.0M, Higher Than $460M-$480M Projected in 2Q >GRAB

2025-11-03 23:14; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Global Equities Roundup: Market Talk

2025-11-03 23:14; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Deterra's Next CEO Might Bring New Approach to Deals -- Market Talk

2025-11-03 23:12; UTC

Uždarbis

Grab Holdings Sees FY2025 Adj Ebitda $490-$500.0M, Higher Than $460M-$480M Projected in 2Q >GRAB

2025-11-03 23:09; UTC

Uždarbis

Grab Holdings 3Q 2Q Adj EBITDA $136.0M Vs. $90.0M>GRAB

2025-11-03 23:09; UTC

Uždarbis

Grab Holdings 3Q Net $17.0M Vs. Net $15.0M >GRAB

2025-11-03 23:09; UTC

Uždarbis

Grab Holdings 3Q Rev $873.0M Vs. $716.0M >GRAB

2025-11-03 23:06; UTC

Rinkos pokalbiai

Uždarbis

Palantir Execs Forecast Future of U.S. Workers In AI World -- Market Talk

2025-11-03 22:36; UTC

Rinkos pokalbiai

Uždarbis

Palantir's U.S. Commercial Business Booms as It Expands AI -- Market Talk

2025-11-03 22:31; UTC

Uždarbis

Franco-Nevada 3Q EPS $1.49 >FNV

2025-11-03 22:31; UTC

Uždarbis

Franco-Nevada 3Q Rev $487.7M >FNV

2025-11-03 22:24; UTC

Rinkos pokalbiai

Xero Bulls Expect Improving U.S. Momentum in 1H -- Market Talk

2025-11-03 22:19; UTC

Įsigijimai, susijungimai, perėmimai

Starbucks Agrees to Sell Stake in China Business -- WSJ

2025-11-03 21:59; UTC

Rinkos pokalbiai

RBA Set To Keep Rates On Hold; Remain Data Dependent -- Market Talk

2025-11-03 21:54; UTC

Rinkos pokalbiai

Uždarbis

Westpac's Tech Challenge Keeps Jefferies Cautious -- Market Talk

2025-11-03 21:54; UTC

Rinkos pokalbiai

Uždarbis

Global Equities Roundup: Market Talk

2025-11-03 21:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-11-03 21:49; UTC

Uždarbis

Palantir Revenue Hits Another Record as Defense Work Booms -- Update

2025-11-03 21:40; UTC

Uždarbis

Barry Diller's IAC Inks AI Deal With Microsoft. That Isn't Why the Stock Is Sliding. -- Barrons.com

2025-11-03 21:31; UTC

Rinkos pokalbiai

Mexican Manufacturing Indexes Pick Up in October -- Market Talk

2025-11-03 21:19; UTC

Uždarbis

Palantir Revenue Hits Another Record as Defense Work Booms -- WSJ

2025-11-03 21:11; UTC

Įsigijimai, susijungimai, perėmimai

Pfizer Reports Earnings Tuesday. Management Has Big Questions to Answer. -- Barrons.com

2025-11-03 21:11; UTC

Uždarbis

Diamondback Energy: Increasing Full Yr Oil Production Guidance to 495-498 MBO/d and Increasing Annual BOE Guidance to 910-920 MBOE/d >FANG

2025-11-03 21:07; UTC

Uždarbis

Palantir Technologies: Raising 2025 U.S. Comml Rev Guidance to in Excess of $1.433B, Representing a Growth Rate of at Least 104% >PLTR

2025-11-03 21:05; UTC

Uždarbis

Vertex Pharmaceutic Sees 2025 Rev $11.9B-$12B >VRTX

2025-11-03 21:05; UTC

Uždarbis

Palantir Technologies 3Q Net $475.6M >PLTR

Akcijų palyginimas

Kainos pokytis

Perspective Therapeutics Inc Prognozė

Kainos tikslas

By TipRanks

379.85% į viršų

12 mėnesių prognozė

Vidutinis 13.1 USD 379.85%

Aukščiausias 18 USD

Žemiausias 5 USD

Remiantis 10 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Perspective Therapeutics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

10 ratings

Pirkti

Laikyti

Parduoti

Remiantis 10 analitikų, pateikusių Perspective Therapeutics Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Finansinės naujienos

Kitos sektoriaus akcijos

JNJ

Johnson and Johnson

187.25

↓-0.16%

ABT

Abbott Laboratories

125.61

↑ +2.29%

TMO

Thermo Fisher Scientific Inc

568.13

↑ +1.65%

ISRG

Intuitive Surgical Inc

536.58

↑ +0.14%

DHR

Danaher Corp

214.86

↑ +0.66%

Perspective Therapeutics Inc

Apžvalga

Akcijų kainos pasikeitimas

Rekomendacijos

Dividendai

Perspective Therapeutics Inc Grafikas

Susijusios naujienos

Akcijų palyginimas

Perspective Therapeutics Inc Prognozė

Kainos tikslas

Bendras įvertinimas

Finansinės naujienos

Kitos sektoriaus akcijos